CRISPR Therapeutics · Buy week 10
Third model window reached: statistical coverage over, residual capital to manage
CRISPR Therapeutics · Buy week 10
In Summary
CRISPR Therapeutics reaches week 10 of an open buy signal. With the third model window now hit, statistical coverage ends — and the trade is still at -5.3% from entry. The confirmation week closed bearish and signal strength is fading: discipline points toward considering an exit rather than adding exposure.
IQS Phase
43
ordinary
Signal Strength
55
medium
Sizing
STANDARD
Ranking
#98 / 135
US stocks in progress
Trade P&L %
-5.29%
from signal to today
restricted Platinum content